Skip to main content

Drug Interactions between Depo Provera and vorasidenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

medroxyPROGESTERone vorasidenib

Applies to: Depo Provera (medroxyprogesterone) and vorasidenib

ADDITIONAL CONTRACEPTION RECOMMENDED: Concomitant use with vorasidenib may decrease the plasma concentrations and efficacy of contraceptive hormones. In vitro studies show that vorasidenib is an inducer of CYP450 3A, the isoenzyme primarily responsible for the metabolic clearance of sex hormones. Decreased hormone concentrations can result in contraception failure and/or increase in breakthrough bleeding. Vorasidenib can cause fetal harm when administered to a pregnant woman.

MANAGEMENT: Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with vorasidenib. Since the use of vorasidenib is likely associated with embryo-fetal harm, it is particularly important that patients not become pregnant during treatment. Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with vorasidenib. Women of childbearing potential should use a highly effective, non-hormonal method of contraception during treatment with vorasidenib and for 3 months after the last dose. Male patients with female partners of reproductive potential should use effective contraception during treatment with vorasidenib and for 3 months after the last dose

References (1)
  1. (2024) "Product Information. Voranigo (vorasidenib)." Servier Pharmaceuticals LLC

Drug and food interactions

Moderate

vorasidenib food

Applies to: vorasidenib

GENERALLY AVOID: Due to induction of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of vorasidenib, smoking tobacco during treatment with vorasidenib may decrease its plasma concentrations and anti-tumor effect. Clinical and pharmacokinetic data are currently lacking.

MANAGEMENT: Patient should be advised to avoid smoking tobacco during treatment with vorasidenib because it may reduce efficacy of the therapy.

References (1)
  1. (2024) "Product Information. Voranigo (vorasidenib)." Servier Pharmaceuticals LLC

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer